146 unknown. 146 Phase 2, 15 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 146 | Unknown 146 |
| Phase 1 | 15 | Unknown 15 |
| Phase 3 | 5 | Unknown 5 |
Follow Otorhinolaryngologic Neoplasms: new trials by email Literature Review of Otorhinolaryngologic Neoplasms trials Research Report on Otorhinolaryngologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma Sintilimab, bevacizumab, gemcitabine, IMRT - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 60 | 2024-04-22 | 2024-04-15 |
| Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Anti-PD1 antibody, nimotuzumab and capecitabine - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Jiangxi Provincial Cancer Hospital | 22 | 2024-02-10 | 2024-03-07 |
| The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy GM-CSF - GM-CSF | Phase 2 | Unknown | Sun Yat-sen University | 138 | 2023-09-15 | 2024-06-25 |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | Phase 1 / Phase 2 | Unknown | Guangxi Medical University | 20 | 2023-08-01 | 2023-06-12 |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies ILB-2109, Toripalimab - Head and Neck Cancer, Cervical Cancer | Phase 1 / Phase 2 | Unknown | Innolake Biopharm | 200 | 2023-07-25 | 2024-05-21 |
| Anrotinib and Tirelizumab in First-line Treatment of RM-NPC Anrotinib plus Tirelizumab - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Zhongshan People's Hospital, Guangdong, China | 27 | 2023-06-01 | 2023-08-08 |
| Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma Iron Isomaltoside 1000, Polysaccharide Iron Complex Pill, Intensity-modulated radiotherapy - Nasopharyngeal Carcinoma, Iron-deficiency | Phase 2 | Unknown | Sun Yat-sen University | 120 | 2023-05-05 | 2023-06-22 |
| Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma Cadonilimab - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2023-04-01 | 2023-03-30 |
| Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tis-U-Sol - Nasopharyngeal Neoplasms | Phase 2 | Unknown | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 100 | 2023-03-01 | 2023-03-06 |
| Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Apatinib, Camrelizumab, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel) - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 84 | 2022-10-08 | 2023-02-08 |
| CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC Dalpiciclib Isetionate Tablets, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 32 | 2022-09-01 | 2023-02-13 |
| PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy Anti-EGFR and PD-1 inhibitor arm - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Fudan University | 41 | 2022-08-01 | 2023-12-05 |
| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Tranilast - Nasopharyngeal Carcinoma, Recurrent Cancer | Phase 2 | Unknown | Jian Guan | 18 | 2022-07-20 | 2023-10-06 |
| Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study Immunotherapy+induction chemotherapy+radiotherapy - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 43 | 2022-07-01 | 2022-06-14 |
| PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC Toxicities reduced treatment, Conventional treatment - Oropharyngeal Cancer | Phase 2 | Unknown | Fudan University | 60 | 2022-06-29 | 2023-12-05 |
| Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 38 | 2022-06-20 | 2022-06-24 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma QL1706, Carrelizumab, Gemcitabine - Nasopharyngeal Carcinoma | Phase 2 / Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 460 | 2022-05-19 | 2023-11-22 |
| Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC endoscopic surgery - Recurrent Nasopharyngeal Carcinoma | Phase 2 | Unknown | Eye & ENT Hospital of Fudan University | 77 | 2022-05-08 | 2022-05-10 |
| Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma Radiotherapy - Metastatic Nasopharyngeal Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 34 | 2022-05-05 | 2024-02-05 |
| PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 32 | 2022-04-30 | 2022-04-22 |
Showing 20 of 146. Sign in to see all of them.
Nasopharyngeal Carcinoma (106) · Nasopharyngeal Neoplasms (28) · Hypopharyngeal Neoplasms (13) · Oropharyngeal Neoplasms (11) · Head and Neck Neoplasms (9) · Laryngeal Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (6) · Mouth Neoplasms (5) · Recurrence (4) · Stomatitis (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (3) · Salivary Gland Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2)
Otorhinolaryngologic Diseases (146) · Neoplasms by Site (145) · Neoplasms (144) · Pharyngeal Diseases (142) · Pharyngeal Neoplasms (142) · Stomatognathic Diseases (142) · Head and Neck Neoplasms (135) · Nasopharyngeal Diseases (126) · Neoplasms by Histologic Type (113) · Carcinoma (111) · Neoplasms, Glandular and Epithelial (111) · Nasopharyngeal Neoplasms (99) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13)
Cisplatin (39) · Gemcitabine (16) · Radiotherapy, Intensity-Modulated (16) · camrelizumab (16) · Docetaxel (15) · toripalimab (13) · Radiotherapy (11) · Drug Therapy (10) · Fluorouracil (9) · apatinib (7) · Endostatins (6) · Paclitaxel (6) · endostar protein (6) · nimotuzumab (6) · sintilimab (6)
Sun Yat-sen University (39) · Fudan University (12) · Zhejiang Cancer Hospital (8) · Fujian Cancer Hospital (6) · Eye & ENT Hospital of Fudan University (4) · Chinese Academy of Medical Sciences (3) · Wei Jiang (3) · Yun-fei Xia (3) · Cancer Hospital of Guangxi Medical University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Copenhagen University Hospital, Rigshospitalet (2) · First People's Hospital of Foshan (2) · Guangxi Medical University (2) · Jiangxi Provincial Cancer Hospital (2) · National University Hospital, Singapore (2)
China (112) · United States (5) · Denmark (2) · Hong Kong (2) · Singapore (2) · Austria (1) · Canada (1) · Israel (1) · Italy (1) · Malaysia (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Chaosu Hu, MD (3) · Lin Kong, MD (3) · Hongmeng Yu, MD,PHD (2) · Ming-yuan Chen, MD, PhD (2) · Xiayun He, M.D. (2) · Yu Wang, M.D. (2) · Yun-fei Xia, M.D (2) · A. Dimitrios Colevas, MD (1) · Arlene A. Forastiere, MD (1) · Aron Popovtzer, MD (1) · Baorui Liu, MD (1) · Bin Li (1) · Bin Zhang, M.D. (1) · Boon Cher Goh (1)
PMID 37580352, PMID 11224527, PMID 15172975, PMID 16382236, PMID 18173375, PMID 19097774, PMID 21319149, PMID 22209574, PMID 22496834, PMID 22562140, PMID 24115004, PMID 24662947, PMID 25198661, PMID 25244494, PMID 26163437, PMID 26429955, PMID 26516369, PMID 27411683, PMID 27609788, PMID 29409313, PMID 29438373, PMID 30046225, PMID 30207593, PMID 31236579, PMID 31448214, PMID 33492986, PMID 33613701, PMID 34043812, PMID 34782428, PMID 34837744, PMID 34990291, PMID 35098345, PMID 35355438, PMID 35623069, PMID 36447152, PMID 36735896, PMID 37540921, PMID 37593221, PMID 37801967, PMID 37951218, PMID 38205914, PMID 39522541, PMID 39636629, PMID 40325445, PMID 40413023, PMID 41158262, PMID 41245547, PMID 41530428, PMID 41813900, PMID 42260486
2017 (2)